This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
January 2020
Presentations

Ladiratuzumab Vedotin | Gastrointestinal Cancer | Abstract TPS469
SGNLVA-005: Open-label, phase 2 study of ladiratuzumab vedotin (LV) for advanced aerodigestive tract malignancies